Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease-Reference-Cited by-同舟云学术

Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease

Published:2020-12-23 Issue:7 Volume:87 Page:2830-2837
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Chrétien Basile¹²^ORCID,Jourdan Jean‐Pierre³⁴^ORCID,Davis Audrey⁴,Fedrizzi Sophie¹²,Bureau Ronan⁴,Sassier Marion¹²,Rochais Christophe⁴^ORCID,Alexandre Joachim¹²⁵,Lelong‐Boulouard Véronique¹⁶,Dolladille Charles¹⁵,Dallemagne Patrick⁴

Affiliation:

1. Department of Pharmacology Caen University Hospital Caen F‐14000 France

2. Pharmacovigilance Regional Center Caen University Hospital Caen F‐14000 France

3. Department of Pharmacy Caen University Hospital Caen F‐14000 France

4. Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN) Normandie Univ, UNICAEN Caen F‐14000 France

5. EA4650, Signalisation, électrophysiologie et imagerie des lésions d'ischémie‐reperfusion myocardique Normandie Univ, UNICAEN Caen 14000 France

6. INSERM UMR 1075, COMETE‐MOBILITES "Vieillissement, Pathologie, Santé" Normandie Univ, UNICAEN Caen 14000 France

Funder

Conseil Régional de Haute Normandie

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14690

Reference58 articles.

1. Drug repositioning: a brief overview

2. Drug repurposing: progress, challenges and recommendations

3. Systematic Drug Repositioning for a Wide Range of Diseases with Integrative Analyses of Phenotypic and Molecular Data

4. Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing Duloxetine as a Potent Butyrylcholinesterase Inhibitor: Potential Cholinergic Enhancing Benefits for Elderly Individuals with Depression and Cognitive Impairment;ACS Omega;2024-08-21

2. Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer;Cancer Epidemiology;2024-06

3. Repurposing of drugs against bacterial infections: A pharmacovigilance‐based data mining approach;Drug Development Research;2024-05-28

4. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems;Frontiers in Drug Safety and Regulation;2024-01-26

5. Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database;Therapeutic Advances in Neurological Disorders;2024-01